These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10360595)

  • 21. Severe renal failure and polyneuritis induced by foscarnet.
    Chatelain E; Deminière C; Lacut JY; Potaux L
    Nephrol Dial Transplant; 1998 Sep; 13(9):2368-9. PubMed ID: 9761526
    [No Abstract]   [Full Text] [Related]  

  • 22. [Acute tubulointerstitial nephritis in HIV infection].
    Möddel M; Pfammatter R; Varga Z; Keusch G
    Praxis (Bern 1994); 2006 Jun; 95(23):949-51. PubMed ID: 16779906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal tolerance of combined treatment with foscarnet and indinavir.
    Guery B; Katlama C; Bochet M; Deray G
    Nephrol Dial Transplant; 1998 Mar; 13(3):815-6. PubMed ID: 9550685
    [No Abstract]   [Full Text] [Related]  

  • 24. [Nephrotic syndrome and acute kidney injury associated with celiac disease: report of one case].
    Vega J; Díaz R; Méndez GR; Goecke H
    Rev Med Chil; 2013 Mar; 141(3):381-7. PubMed ID: 23900331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapidly progressive glomerulonephritis associated with rifampicin therapy for pulmonary tuberculosis.
    Murray AN; Cassidy MJ; Templecamp C
    Nephron; 1987; 46(4):373-6. PubMed ID: 3658067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimising the dosage-limiting toxicities of foscarnet induction therapy.
    Jayaweera DT
    Drug Saf; 1997 Apr; 16(4):258-66. PubMed ID: 9113493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Salt-wasting nephropathy induced by foscarnet treatment for HHV-6 encephalitis in a hematopoietic stem cell transplant].
    Najima Y; Ohashi K; Ando M; Koshida A; Yamashita T; Akiyama H; Sakamaki H
    Rinsho Ketsueki; 2008 Jan; 49(1):40-5. PubMed ID: 18277595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between renal dysfunction and electrolyte abnormalities in hematopoietic stem cell transplant patients treated with foscarnet.
    Ota R; Hirata A
    J Chemother; 2021 Dec; 33(8):539-546. PubMed ID: 34060436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
    Ehlert K; Groll AH; Kuehn J; Vormoor J
    Klin Padiatr; 2006; 218(3):180-4. PubMed ID: 16688677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversible acute renal failure in idiopathic nephrotic syndrome.
    Furuya R; Kumagai H; Ikegaya N; Kobayashi S; Kimura M; Hishida A; Kaneko E
    Intern Med; 1993 Jan; 32(1):31-5. PubMed ID: 8495041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients.
    Ringdén O; Lönnqvist B; Paulin T; Ahlmén J; Klintmalm G; Wahren B; Lernestedt JO
    J Antimicrob Chemother; 1986 Mar; 17(3):373-87. PubMed ID: 3009383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Penile erosions associated with foscarnet therapy in a child.
    Hick RW; Prose N
    Pediatr Dermatol; 2010; 27(3):302-3. PubMed ID: 20609154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute renal failure induced by foscarnet: 4 cases.
    Cacoub P; Deray G; Baumelou A; Le Hoang P; Rozenbaum W; Gentilini M; Soubrie C; Rousselie R; Jacobs C
    Clin Nephrol; 1988 Jun; 29(6):315-8. PubMed ID: 2840226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical and pathological analysis of IgA nephropathy with acute kidney injury].
    Chen MG; Ye XH; Liang HY; Yang Q
    Zhonghua Er Ke Za Zhi; 2016 Aug; 54(8):610-3. PubMed ID: 27510875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-associated immune complex glomerulonephritis with "lupus-like" features: a clinicopathologic study of 14 cases.
    Haas M; Kaul S; Eustace JA
    Kidney Int; 2005 Apr; 67(4):1381-90. PubMed ID: 15780090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Forscarnet-induced tubulointerstitial nephritis in renal transplant patients.
    Nyberg G; Blohmé I; Persson H; Svalander C
    Transplant Proc; 1990 Feb; 22(1):241. PubMed ID: 2137949
    [No Abstract]   [Full Text] [Related]  

  • 38. Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients.
    Bacigalupo A; Boyd A; Slipper J; Curtis J; Clissold S
    Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1249-64. PubMed ID: 23167560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute renal failure associated with foscarnet therapy.
    Navarro JF; Mora C; Gallego E; García J
    Nephrol Dial Transplant; 1996 Jan; 11(1):221. PubMed ID: 8649644
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients.
    Reusser P; Gambertoglio JG; Lilleby K; Meyers JD
    J Infect Dis; 1992 Sep; 166(3):473-9. PubMed ID: 1323614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.